HRT Investor Notice: Robbins LLP Reminds Stockholders it is Investigating the Acquisition of HireRight Holdings Corp.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of HireRight Holdings Corp. (NYSE: HRT) by investment funds affiliated with General Atlantic, L.P. and Stone Point Capital LLC (the "Sponsors"). Under the terms of the agreement, the Sponsors will acquire all the outstanding shares they do not already own for $14.35 per share in cash.

If you own shares of HireRight Holdings Corp. click here.

Is the Proposed Acquisition Best for HireRight Holdings Corp. (HRT) and its Shareholders?

On February 16, 2024, HireRight announced a deal to be acquired by the Sponsors. According to the Proxy Statement, HireRight's board of directors approved the merger agreement for $14.35 per share in cash. The deal is valued at approximately $1.65 billion and is expected to close mid-2024. Robbins LLP is concerned that HireRight's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of HireRight Holdings Corp. (HRT) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion in value for shareholders. To be notified if a class action against HireRight Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NYSE:HRT

Release Summary

Robbins LLP is investigating the acquisition of HireRight Holdings Corp. (HRT)

Release Versions

English

$Cashtags

$HRT

Hashtags

#GeneralAtlanticLP

#HireRightHoldingsCorp

#StonePointCapitalLLC

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles

Robbins LLP

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Super Micro Computer, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers. For more information, submit a form,...

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...

Back to Newsroom